

Pyoderma gangrenosum - Pipeline Insight, 2021

<https://marketpublishers.com/r/PCA7E6E783BCEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PCA7E6E783BCEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Pyoderma gangrenosum - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Pyoderma gangrenosum pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pyoderma gangrenosum Understanding

Pyoderma gangrenosum: Overview

Pyoderma gangrenosum (PG) is an inflammatory skin disorder that is characterized by small, red bumps or blisters (papules or nodules) that eventually erode to form swollen open sores (ulcerations). The size and depth of the ulcerations vary greatly, and they are often extremely painful. In approximately 50 percent of cases, PG occurs secondary to another disorder such as inflammatory bowel disease. The exact cause of PG is unknown (idiopathic). Some researchers believe it may be an autoimmune disorder.

'Pyoderma gangrenosum - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pyoderma gangrenosum pipeline landscape is provided which

includes the disease overview and Pyoderma gangrenosum treatment guidelines. The assessment part of the report embraces, in depth Pyoderma gangrenosum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pyoderma gangrenosum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pyoderma gangrenosum R&D. The therapies under development are focused on novel approaches to treat/improve Pyoderma gangrenosum.

Pyoderma gangrenosum Emerging Drugs Chapters

This segment of the Pyoderma gangrenosum report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pyoderma gangrenosum Emerging Drugs

Vilobelimab: InflaRx

InflaRx's lead drug candidate, vilobelimab (IFX-1), is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications including Pyoderma Gangraenosum (PG), a rare ulcerative skin disorder. InflaRx is currently conducting a Phase II clinical study to investigate a potential benefit of vilobelimab (IFX-1) for patients suffering from PG. This study is currently recruiting patients.

Ixekizumab: Eli Lilly and Company

Ixekizumab is a humanized IgG4 monoclonal antibody developed by Eli Lilly & Company for the treatment of autoimmune diseases. It was designed specifically to bind interleukin-17A (IL-17A) and produced by recombinant DNA technology in a recombinant mammalian cell line. The drug is in phase 2 of clinical trials for the treatment of patients with Pyoderma Gangraenosum.

Further product details are provided in the report

Pyoderma gangrenosum: Therapeutic Assessment

This segment of the report provides insights about the different Pyoderma gangrenosum drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pyoderma gangrenosum

There are approx. 3+ key companies which are developing the therapies for Pyoderma gangrenosum. The companies which have their Pyoderma gangrenosum drug candidates in the most advanced stage, i.e. phase II include, InflaRx.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Pyoderma gangrenosum pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pyoderma gangrenosum: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pyoderma gangrenosum therapeutic

drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pyoderma gangrenosum drugs.

Pyoderma gangrenosum Report Insights

Pyoderma gangrenosum Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Pyoderma gangrenosum Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pyoderma gangrenosum drugs?

How many Pyoderma gangrenosum drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pyoderma gangrenosum?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pyoderma gangrenosum therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pyoderma gangrenosum and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

InflaRx

Aclaris Therapeutics

Eli Lilly and Company

Novartis

Key Products

Vilobelimab

ATI 450

Ixekizumab

Research programme: mitogen-activated protein kinase-activated protein kinase-2 pathway inhibitors

Secukinumab

Contents

Introduction

Executive Summary

Pyoderma gangrenosum: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Pyoderma gangrenosum – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Pyoderma gangrenosum companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Pyoderma gangrenosum Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

Vilobelimab: InflaRx

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Pyoderma gangrenosum Key Companies

Pyoderma gangrenosum Key Products

Pyoderma gangrenosum- Unmet Needs

Pyoderma gangrenosum- Market Drivers and Barriers

Pyoderma gangrenosum- Future Perspectives and Conclusion

Pyoderma gangrenosum Analyst Views

Pyoderma gangrenosum Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Pyoderma gangrenosum
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Pyoderma gangrenosum
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Pyoderma gangrenosum - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PCA7E6E783BCEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PCA7E6E783BCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970